Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August

Medisol Acquisition To Push Injectables Growth

Lupin has pushed the launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables

FDA Approval Stamp
Lupin Awaits FDA Action On A Spiriva Generic • Source: Shutterstock

More from Business

More from Scrip